WAYNE, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that it will report its second quarter 2026 financial results before market open on Tuesday, August 4, 2026. Palvella management will host a conference call for investors at 8:30 a.m. ET on that same day to discuss the results and provide a corporate update.
Read more at globenewswire.comThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Nvidia%20logo%20by%20Konstantin%20Savusia%20via%20Shutterstock.jpg)
/Space/Rocket%20launch%20by%20Alones%20via%20Shutterstock.jpg)
/Business%20process%20analysis%20and%20network%20connectivity%20by%20THAWEERAT%20via%20Adobe%20Stock.jpeg)